ArticleInternational journal of molecular sciences2025
Synergistic Production of Lycopene and β-Alanine Through Engineered Redox Balancing in
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterisation of metabolic burden in Pseudomonas putida reveals precursor limitation in heterologous lycopene production.Microbial cell factories · 2026Article
- Yeast Stress Response to Synthetic Constructs.ACS synthetic biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The production of β-alanine from fatty acid feedstocks presents a promising synthetic strategy due to its high carbon yield. However, the excessive reducing power generated during fatty acid utilization disrupts cellular redox balance, adversely affecting metabolism and limiting the efficiency and final yield of β-alanine production. To address this challenge, we engineered a co-production system in which excess reducing equivalents generated during fatty acid β-oxidation and β-alanine biosynthesis were consumed by growth-coupled lycopene biosynthesis. The resulting dual-pathway strain, SA01, achieved 44.78 g/L β-alanine and 3.07 g/L lycopene in bioreactor fermentation, representing a 21.45% increase in β-alanine production compared to the β-alanine-producing strain WA01, and a 74.43% increase in lycopene production compared to the lycopene-producing strain LA01. Further optimization in strain SA06, involving cofactor engineering to shift redox flow from NADH to NADPH, enhanced the titers to 52.78 g/L β-alanine and 3.61 g/L lycopene. Metabolite analysis confirmed a decrease in intracellular NADH and FADH
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.